SLCO5A1 and synaptic assembly genes contribute to impulsivity in juvenile myoclonic epilepsy
- PMID: 37770509
- PMCID: PMC10539321
- DOI: 10.1038/s41525-023-00370-z
SLCO5A1 and synaptic assembly genes contribute to impulsivity in juvenile myoclonic epilepsy
Abstract
Elevated impulsivity is a key component of attention-deficit hyperactivity disorder (ADHD), bipolar disorder and juvenile myoclonic epilepsy (JME). We performed a genome-wide association, colocalization, polygenic risk score, and pathway analysis of impulsivity in JME (n = 381). Results were followed up with functional characterisation using a drosophila model. We identified genome-wide associated SNPs at 8q13.3 (P = 7.5 × 10-9) and 10p11.21 (P = 3.6 × 10-8). The 8q13.3 locus colocalizes with SLCO5A1 expression quantitative trait loci in cerebral cortex (P = 9.5 × 10-3). SLCO5A1 codes for an organic anion transporter and upregulates synapse assembly/organisation genes. Pathway analysis demonstrates 12.7-fold enrichment for presynaptic membrane assembly genes (P = 0.0005) and 14.3-fold enrichment for presynaptic organisation genes (P = 0.0005) including NLGN1 and PTPRD. RNAi knockdown of Oatp30B, the Drosophila polypeptide with the highest homology to SLCO5A1, causes over-reactive startling behaviour (P = 8.7 × 10-3) and increased seizure-like events (P = 6.8 × 10-7). Polygenic risk score for ADHD genetically correlates with impulsivity scores in JME (P = 1.60 × 10-3). SLCO5A1 loss-of-function represents an impulsivity and seizure mechanism. Synaptic assembly genes may inform the aetiology of impulsivity in health and disease.
© 2023. Springer Nature Limited and Centre of Excellence in Genomic Medicine Research, King Abdulaziz University.
Conflict of interest statement
D.A., K.K.S., R.H.T. and J.Z. report honoraria from UCB Pharma (manufacturer of levetiracetam) and R.H.T. reports honoraria from Sanofi (manufacturer of sodium valproate). K.H. reports honoraria from UCB Pharma, Eisai and GW Pharma. M.S. reports honoraria from UCB Pharma and Eisai. G.R. reports honoraria from UCB Pharma (manufacturer of levetiracetam), from EISAI (manufacturer of perampanel), from Angelini Pharma (manufacturer of cenobamate). R.H.T. reports honorarium from Arvelle/Angelini, Bial, Eisai, GW Pharma/Jazz, Zogenix. All other authors report no competing interests.
Figures




References
-
- Daruna, J. H. & Barnes, P. A. In: The impulsive client: theory, research and treatment (eds W. G. McCown, J. L. Johnson, & M. B. Shure) 23–37 (American Psychological Association, 1993).
-
- Dalley JW, Robbins TW. Fractionating impulsivity: neuropsychiatric implications. Nat. Rev. Neurosci. 2017;18:158–171. - PubMed
-
- Ramirez-Martin A, Ramos-Martin J, Mayoral-Cleries F, Moreno-Kustner B, Guzman-Parra J. Impulsivity, decision-making and risk-taking behaviour in bipolar disorder: a systematic review and meta-analysis. Psychol. Med. 2020;50:2141–2153. - PubMed
-
- Smith A, Syvertsen M, Pal DK. Meta-analysis of response inhibition in juvenile myoclonic epilepsy. Epilepsy Behav. 2020;106:107038. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases